Neutrogena(R) Dermatologics Introduces skin iD(TM), the First Personalized Acne Solution

Thu Jun 12, 2008 11:25am EDT

* Reuters is not responsible for the content in this press release.

Neutrogena(R) Dermatologics Introduces skin iD(TM), the First Personalized
Acne Solution
Clinically proven to be 2X more effective in acne clearing, and 2X more
effective in acne prevention vs. the leading acne system

LOS ANGELES, June 12 /PRNewswire/ -- Neutrogena(R) Dermatologics, a unit
of the #1 dermatologist recommended skincare brand Neutrogena(R), introduces
skin iD(TM), the first personalized acne solution clinically proven to treat
and prevent acne.  skin iD is a precise, targeted and individualized approach
to treating and preventing acne.
    (Photo:  http://www.newscom.com/cgi-bin/prnh/20080612/NYTH030 )
    In a clinical trial testing 500 people with different skin, acne and
lifestyles, 100% of people using skin iD got clearer, healthier-looking skin.
skin iD is currently the only non-prescription acne solution on the market
that has conducted a double blind, randomized, placebo-controlled clinical
trial -- the "gold standard" in testing methodology. This clinical trial
demonstrated skin iD's power to work significantly better than the top selling
acne regimen in treating 16 different signs of acne.
    skin iD was developed by Neutrogena(R) Dermatologics with a group of
leading dermatologists, scientists and market researchers, charged to create a
customized skin-clearing solution specifically designed to treat acne on a
case-by-case basis without a prescription.  skin iD is comprised of a skin
evaluation, an exclusive product line and a comprehensive Web site to treat
each individual's acne needs.
    Exclusively available on skiniD.com, and showcased through a series of
infomercials, skin iD is the first proposition of its kind on the market. "We
wanted to create a highly effective acne solution to meet the needs of
individuals who are not satisfied with their existing acne regimen," states
Jim Colleran, President, Neutrogena Corporation. "skin iD was developed with
an innovative one-on-one approach.  We determined that offering consumers
access to skin iD through a dedicated Web site or by phone would allow for the
dialogue necessary to evaluate their unique skincare needs and provide a
personalized regimen."
    skin iD utilizes a breakthrough skin and lifestyle evaluation tool, which
contains a patent-pending algorithm that provides a personalized skincare
regimen based on the specific skincare needs of each individual consumer.
skin iD is formulated with two leading acne-fighting medicines, Salicylic Acid
and Benzoyl Peroxide, included in more than 25 customized acne skincare
regimens that cleanse, treat and protect for significantly improved skin.
    To launch skin iD, Neutrogena(R) Dermatologics has enlisted singer/actress
Katharine McPhee. Best known for her success on "American Idol" and her first
single "Somewhere Over the Rainbow," McPhee is truly a role model for young
girls, who understands the emotional impact associated with acne and the
importance of finding a solution.  Katharine will appear in infomercials and
be featured on skiniD.com beginning in May 2008. McPhee will make her big
screen debut in August, starring in "The House Bunny" opposite Anna Farris,
Emma Stone and Kat Dennings for Sony Pictures.
    About Neutrogena(R):
    A worldwide leader in premium, dermatologist-recommended skin, hair and
cosmetics products, Neutrogena(R) Corporation has been providing consumers
with health and beauty improvements for over 40 years. The Company
manufactures and markets a line of premium priced skin and hair care products
that are distributed in more than 70 countries.  Headquartered in Los Angeles,
Neutrogena(R) is a subsidiary of Johnson & Johnson, world's most comprehensive
and broadly based health care products company.
SOURCE  Neutrogena

Caitlin Rimgaila, Rpr Marketing Communications, +1-212-317-1462,
Caitlin.Rimgaila@rprny.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.